Please use this identifier to cite or link to this item:
http://localhost:8080/xmlui/handle/123456789/9320
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chou, Shih-Hsiu | - |
dc.contributor.author | Wan, Tsai-Wen | - |
dc.contributor.author | Shiau, Chung-Wai | - |
dc.contributor.author | Chen, Ling-Han | - |
dc.contributor.author | Lin, Hsueh-Chun | - |
dc.contributor.author | Chiu, Hao-Chieh | - |
dc.date.accessioned | 2024-12-19T04:08:27Z | - |
dc.date.available | 2024-12-19T04:08:27Z | - |
dc.date.issued | 2023-06 | - |
dc.identifier.citation | Original Article | en_US |
dc.identifier.uri | http://localhost:8080/xmlui/handle/123456789/9320 | - |
dc.description.abstract | Abstract Background/purpose: The increasing incidence of infections caused by multidrugresistant Salmonella enterica has become a serious threat to global public health. Here, we found that the tyrosine kinase inhibitor nilotinib exhibits antibacterial activity against intracellular S. enterica serovar Typhimurium in RAW264.7 macrophages. Thus, we aimed to pharmacologically exploit the anti-intracellular Salmonella activity of nilotinib and to elucidate its mechanism of action. Methods: The antibacterial activity of the compounds was assessed by high-content analysis (HCA) and intracellular CFU, minimum inhibitory concentration (MIC), and bacterial growth assays. The cytotoxicity of the compounds was evaluated by HCA and a 3-(4,5-dimethylthiazol-2- yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) cell viability assays. The levels of cellular AMPK, phospho-AMPK, Atg7 and b-actin were determined by immunoblotting. Results: The screen identified two small molecule compounds (SCT1101 and SCT1104) with potent activity against intracellular S. Typhimurium. Moreover, SCT1101 and SCT1104 enhanced the efficacy of ciprofloxacin and cefixime against intracellular S. Typhimurium. However, only SCT1101 exhibited activity against intracellular MDR and fluoroquinolone-resistant S. Typhimurium isolates. Subsequent mechanistic studies showed that neither of these nilotinib | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier Taiwan LLC | en_US |
dc.subject | AMPK | en_US |
dc.subject | Autophagy | en_US |
dc.subject | High-content analysis | en_US |
dc.subject | Metformin | en_US |
dc.subject | AICAR | en_US |
dc.title | Repurposing the tyrosine kinase inhibitor nilotinib for use against intracellular multidrug-resistant Salmonella Typhimurium | en_US |
dc.type | Article | en_US |
Appears in Collections: | VOL 56 NO 3 2023 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
490-498.pdf | 952.9 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.